Targeting H19X-encoded non-coding RNAs to treat muscle wasting, cachexia, sarcopenia and heart failure
Provided here are compositions and methods of preventing or treating a muscle disorder in a subject, such as muscle wasting, cachexia, sarcopenia and heart failure. The compositions include inhibitors targeting one or more of the H19X-encoded non-coding RNAs. The inhibitors can inhibit expression of one or more of the H19X-encoded non-coding RNAs or inhibit interaction between one or more of the H19X-encoded non-coding RNAs and their natural target mRNA. Also, provided are methods of preventing or treating a muscle disorder in a subject by inducing specific mutations to decrease expression of one or more of the H19X-encoded non-coding RNAs utilizing gene editing tools such as, but not limited to, integrases, CRISPR/Cas nucleases, TALAN nucleases, zinc finger Nucleases, triplex forming oligonucleotides, or combinations thereof.
Patents
63/269,975 (Provisional, Pre-Conversion)
Case ID
2022-013
Inventor
Yu Liu
Associate Professor, Biology and Biochemistry
Contact
Category